SPH5030 for HER2-positive advanced solid tumors
Part of Cancer clinical trials.
This early-stage study tests SPH5030 tablets in people with HER2-positive advanced solid tumors that have not responded to standard treatment or have no standard option. It aims to see whether the treatment can shrink tumors and is safe enough to move forward.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your cancer is HER2-positive and has spread (metastatic) or is advanced solid tumor type.
- You have already had standard treatment that didn’t work, or there is no standard treatment available for you.
- You are well enough for the study: your daily function is about normal or only slightly limited (ECOG 0–1).
- You have at least one measurable tumor spot that can be followed on scans.
- Your blood tests are adequate (infection-fighting white cells, platelets, and hemoglobin) and your liver/kidney function are within limits.
- No serious ongoing issues: any past treatment side effects are back to baseline (or mild), and you can swallow tablets and absorb them well.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medication (SPH5030) for people with advanced colorectal or biliary tract cancer whose tumors have a specific marker called HER2. It may offer a treatment option if previous therapies have stopped working.
This phase 1 trial tests a new oral drug called SPH7485 for people with advanced solid tumors that have not responded to other treatments. The goal is to see if the drug is safe and effective.
This trial studies SPH4336 given together with standard hormone (endocrine) therapy for breast cancer that has spread or cannot be treated with surgery. It aims to see whether the combination is safer and more effective than hormone therapy alone.
This early-phase study tests SPH4336 alone or combined with an immunotherapy drug called cadonilimab in people with advanced solid cancers that can’t be cured with surgery or local treatments. It aims to find out how safe it is and whether it can shrink tumors or control the disease.
This trial tests an investigational drug for people with advanced or metastatic HER2-positive solid tumors. The drug is designed to target cancer cells with HER2 and may slow tumor growth.
This trial tests an investigational drug (SHR-4602) alone or with other treatments for advanced solid tumors that have HER2. The goal is to see if it can shrink or control the cancer.
Hear when a new HER2-positive Advanced Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.